New Mexico Minority-Based Community Clinical Oncology Program

描述（申请人提供）： 由于西班牙裔和美洲印第安人的比例最高（42%西班牙裔和10%美洲印第安人），新墨西哥州的190万人有巨大的癌症健康差异。新墨西哥州的人均收入仅排在第47位，人口相对年轻，贫困（27%），没有保险（22%）。近50%的人生活在农村地区，获得医疗保健的机会有限。由NCI SEER项目的创始成员之一的新墨西哥州肿瘤登记处追踪，新墨西哥州的多种族人群的癌症发病率和死亡率模式截然不同。虽然北方新墨西哥州的西班牙裔主要来自早期的西班牙土地授予家庭，但南部新墨西哥州的西班牙裔更经常是墨西哥血统。新墨西哥州的部落社区特别多样化，有19个普韦布洛人、纳瓦霍民族和三个纳瓦霍部落，以及Jouzilla和梅斯卡莱罗阿帕奇人。在这种丰富的背景下，新墨西哥州少数民族社区临床肿瘤学计划（NM MBCCOP）的目标是通过癌症教育和外展计划建立社区临床研究能力，并克服重大的社会经济和文化障碍，以增加获得和增加NCI赞助的癌症治疗和预防临床试验。自2000年（U10 CA 86780）以来，NM MBCCOP一直在努力建立一个全州范围的社区临床试验协作网络（新墨西哥州癌症护理联盟（NMCCA）），通过与共享治理、单一IRB和综合运营的合作法律的协议。102名医生参与者（61名A类和41名B类）覆盖整个州。NM MBCCOP和NMCCA的主要监管和数据管理职能位于新墨西哥州大学癌症中心（UNMCC），以及其他8个组成部分和2个附属社区站点。NMCCA主要负责在社区环境中实施和管理NM MBCCOP。在上一个供资期间，地中海北部的医疗保健CCOP超过了其应计目标，平均每年有85.7个治疗和65.34个预防/控制应计信用额。治疗试验应计利润增加了25%。在上一个资助期内，NM MBCCOP试验累计了521例患者，其中319例（61.2%）为少数民族（180例西班牙裔，36例美洲印第安人和103例混合种族，其他少数民族或未申报）。NM MBCCOP现在准备大幅增加总体应计费用，并改进其预防和癌症控制临床试验菜单，以增加预防和控制试验的应计费用。总之，NM MBCCOP拥有强大的、运作良好的全州基础设施、成功的应计记录和未来增长的战略计划。

Description (provided by applicant): With the highest proportion of Hispanics and American Indians of any State (42% Hispanic, and 10% American Indian), New Mexico's 1.9 million people have tremendous cancer health disparities. Ranking only 47th in per capita income, New Mexico's population is relatively young, poor (27%), and uninsured (22%). Nearly 50% live in rural areas with limited access to healthcare. Tracked by The New Mexico Tumor Registry, a founding member of the NCI SEER Program, New Mexico's multiethnic populations has strikingly different patterns of cancer incidence and mortality. While Northern NM Hispanics are derived primarily from early Spanish land grant families, Southern NM Hispanics are more frequently of Mexican descent. The Tribal communities of New Mexico are particularly diverse, with 19 Pueblos, the Navajo Nation and three Navajo Bands, and the Jicarilla and Mescalero Apaches. In this rich context, the goals of The New Mexico Minority-Based Community Clinical Oncology Program (NM MBCCOP) are to build community capacity for clinical research through cancer education and outreach programs, and, to overcome significant socioeconomic and cultural barriers to increase access and accrual to NCI-sponsored cancer treatment and prevention clinical trials. Funded since 2000 (U10CA86780), the NM MBCCOP has worked diligently to build a build a collaborative statewide community clinical trials network (The New Mexico Cancer Care Alliance (NMCCA)) through cooperating legal agreements with shared governance, a single IRB, and integrated operations. The 102 physician participants (61 types A and 41 type B) cover the entire State. The primary regulatory and data management functions of the NM MBCCOP and the NMCCA are located at The University of New Mexico Cancer Center (UNMCC) with 8 other component and 2 affiliate community sites. The NMCCA is primarily responsible for implementing and managing the NM MBCCOP in community settings. In the past funding period, the NM MBCCOP surpassed its accrual goals, averaging 85.7 annual therapeutic and 65.34 annual prevention/control accrual credits. Therapeutic trial accruals have increased 25%. In the last funding period, 521 patients were accrued to NM MBCCOP trials, 319 (61.2%) of whom were ethnic minorities (180 Hispanic, 36 American Indian, and 103 mixed race, other minority, or undeclared). The NM MBCCOP is now poised to significantly increase overall accrual and to improve its prevention and cancer control clinical trial menu in order to increase accrual to prevention and control trials. In summary, the NM MBCCOP has a strong, well functioning statewide infrastructure, a successful accrual record, and a strategic plan for future growth.